Haloperidol

Apnea, coma, bradycardia, arrhythmia, heart arrest, and death have been reported with concomitant use.

Co-administration may lead to torsade de pointes-type ventricular tachycardia due to QT prolongation. Avoid concomitant use.

Avoid use; may prolong QT interval and increase risk of arrhythmias with anagrelide.

Avoid concomitant use due to QT prolongation risk.

Butyrophenone antipsychotics potentiate the CNS-depressant action of clonazepam.

High intravenous doses of clonidine may increase arrhythmogenic potential (QT-prolongation, ventricular fibrillation) of high intravenous doses of haloperidol, though causal relationship unclear.

Has strong central antidopaminergic properties and suppresses dopaminergic renal and mesenteric vasodilation at low infusion rates.

QT-prolonging drug with known torsades de pointes risk. Combined with fingolimod's QT prolongation and bradycardia effects, patients require overnight continuous ECG monitoring in medical facility.

QT-prolonging drug associated with torsades de pointes risk. Patients require overnight continuous ECG monitoring in medical facility during fingolimod initiation.

Potential for elevation of haloperidol levels with risk of toxicity.

Haloperidol serum levels may be decreased, resulting in worsening of schizophrenic symptoms and tardive dyskinesia development. Closely monitor if coadministration unavoidable.

Haloperidol serum levels may decrease when coadministered with glycopyrrolate, resulting in worsening schizophrenic symptoms and tardive dyskinesia development. Closely monitor if coadministration cannot be avoided.

Combined use may cause encephalopathic syndrome with neurological toxicity, weakness, lethargy, fever, tremor, confusion, and irreversible brain damage in some patients. Close monitoring required.

Antipsychotic that prolongs QTc interval and increases risk for Parkinsonism, NMS, and akathisia when used concomitantly with tetrabenazine.

Antipsychotic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitoring.

Venlafaxine decreases oral-dose clearance of haloperidol by 42%, resulting in 70% increase in haloperidol AUC and 88% increase in Cmax.

Venlafaxine decreases haloperidol clearance by 42%, increases AUC by 70%, and increases Cmax by 88%, resulting in significantly elevated haloperidol exposure.

Antipsychotic drug haloperidol may interact with benztropine mesylate; concurrent use requires monitoring per WARNINGS section.

Haloperidol is a butyrophenone dopamine antagonist that results in decreased efficacy of bromocriptine mesylate.

CYP2D6 substrate; bupropion inhibits CYP2D6 and increases haloperidol concentrations; consider dose reduction.

Bupropion inhibits CYP2D6 and can increase haloperidol concentrations; consider dose reduction of haloperidol.

CYP2D6 substrate antipsychotic. Bupropion inhibits CYP2D6, increasing haloperidol exposure. Dose reduction may be necessary.

CYP2D6 substrate antipsychotic. Bupropion inhibits CYP2D6 and can increase haloperidol concentrations. Consider dose reduction of haloperidol when used with bupropion.

CYP2D6-metabolized antipsychotic. Bupropion inhibits CYP2D6 and can increase haloperidol concentrations. Consider dose reduction.

Concomitant administration resulted in increased serum haloperidol concentrations; clinical significance unclear.

Haloperidol increases plasma concentration of clomipramine.

Haloperidol increases plasma concentration of clomipramine; close supervision and dosage adjustment recommended.

Haloperidol blocks dopamine receptors, inhibiting the central stimulant effects of amphetamines.

QT prolonging drug with torsades de pointes risk. Monitor overnight with continuous ECG in medical facility during initiation.

Potential for elevation of haloperidol levels.

May induce hyperammonemia. Monitor ammonia levels closely when used concomitantly in patients with UCDs.

Drug interactions may occur when hyoscyamine sulfate is used with haloperidol.

Potent CYP2D6 inhibitor may increase plasma concentration of metoprolol, decreasing cardioselectivity.

Potent CYP2D6 inhibitor may increase metoprolol plasma concentration, decreasing cardioselectivity.

Extrapyramidal effects of haloperidol can be potentiated by metyrosine's inhibition of catecholamine synthesis. Caution should be observed.

Bupropion inhibits CYP2D6 and can increase haloperidol concentrations. Consider dose reduction when using with CONTRAVE.

Nefazodone decreased haloperidol apparent clearance by 35% with unknown clinical significance. Dosage adjustment of haloperidol may be necessary.

Elevated haloperidol levels have been observed with coadministration.

Rifapentine may increase metabolism and decrease activity. Dosage adjustment may be necessary.

May increase plasma ammonia level; monitor ammonia levels closely.

Suspected of causing SIADH; may increase pressor and antidiuretic effects of vasopressin. Hemodynamic monitoring recommended.

May cause SIADH, increasing pressor and antidiuretic effects of vasopressin. Hemodynamic monitoring recommended; adjust vasopressin dose as needed.

Venlafaxine increases haloperidol AUC and Cmax. Caution recommended with co-administration.

No effect on pharmacokinetics or pharmacodynamics of zolpidem after single-dose administration.

No effect of haloperidol on the pharmacokinetics or pharmacodynamics of zolpidem observed in single-dose study.

Antipsychotic drug haloperidol interacts with benztropine; interaction details referenced in WARNINGS section.

Concomitant administration resulted in increased serum haloperidol concentrations; clinical significance unclear.